Back to All

ASCO Daily Highlights: Monday 3rd June

4 June, 2024

ASCO daily highlights: Monday 3rd June

Read our 5 key highlights from day 4 at ASCO:

  1. BRAF V600E mCRC continues to be a disease with a poor prognosis in need of novel therapeutic approaches. Biomarker-driven patient stratification may be needed to further identify potential patients among the BRAF V600E mCRC cohort who might benefit from ERAS-007 treatment.

  2. Highly sensitive techniques is needed to detect small fragments of tumor-specific alterations in the background of cell-free DNA from non-cancerous cells, and prospective validation is required before such assays can be used to guide therapy outside of the clinical trial setting.

  3. TUC+Trasis is an important chemotherapy-free treatment option in HER2+ mCRC. Results from upcoming phase III MOUNTAINEER trial will support its use as a 1L treatment (dual HER2 targeted therapy) for patients with HER2+ mCRC.

  4. Results from CodeBreaKsupport trial support the use of soto960+pani as a potential SOC for patients with
    chemorefractory KRAS G12C-mutated mCRC. Not all targeted therapies will show superior therapeutic activity. Treatment choices should be carefully evaluated in combination with an individual's biomarker testing results and treatment history.

  5. ADC target expression matter: selecting patients based on target (c-Met) expression is clinically relevant and criticalpatient selection for ABBV-400 in CRC patients.

    If you missed us at ASCO, and would like to learn more about how we can support your commercialization strategy, contact us here: Contact Us - Diaceutics


Abstract 3517 “Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.”

Abstract 3009 “Performance characteristics of a tissue-agnostic genome-wide methylome enrichment MRD assay for head and neck malignancies.”; abstract 3010 “Personalized cell-free tumor DNA analysis for patients with HNSCC: Liquid biopsy for minimal residual disease detection in head and neck squamous cell carcinoma (LIONESS).”; abstract 3011 “Circulating tumor cells and tumor DNA in patients with resectable colorectal liver metastases: The MIRACLE.”

Abstract LBA3510 “Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).”

Abstract 3509 “Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).”

Abstract 3515 “First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer.”

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny